Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Locally Advanced Cervical Carcinoma 1Head and Neck Neoplasms 1Advanced Refractory Solid Tumors 1

Interventions

Etoposide 15Carboplatin 14Cisplatin 9anlotinib 8PM 01183 6toripalimab 5Drug Therapy 5tislelizumab 4atezolizumab 4Topotecan 4Radiotherapy 4Platinum 4irinotecan sucrosofate 3durvalumab 3famitinib 2apatinib 2Pemetrexed 2Paclitaxel 2EC regimen 2sintilimab 1osimertinib 1nintedanib 1fludarabine 1amrubicin 1Tomography, X-Ray Computed 1Tissue Banks 1Radiation Dose Hypofractionation 1Rabeprazole 1Proton Pump Inhibitors 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Small Cell Lung Carcinoma × Radiation Dose Hypofractionation × Clear all
NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
25 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡